ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma - Top-Institutions - MDSpire

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma

Dana-Farber Cancer Institute investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial, a first-of-its-kind randomized trial of teclistamab, a BCMA-targeted bispecific antibody, in high-risk smoldering multiple myeloma.

  • By

  • June 14, 2026

  • 4 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology

  • #2

    Moffitt Cancer Center
    Moffitt Cancer Center

    Tampa, FL

    Key Differentiators

    • Hematology

  • #3

    Atrium Health Levine Cancer Institute
    Atrium Health Levine Cancer Institute

    Charlotte, NC

    Key Differentiators

    • Hematology

  • #4

    Harvard Medical School
    Harvard Medical School

    Boston, MA

    Key Differentiators

    • Hematology

  • #5

    National and Kapodistrian University of Athens
    National and Kapodistrian University of Athens

    Athens, Greece

    Key Differentiators

    • Hematology

Original Source(s)

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma

  • by

  • June 14, 2026

Related Content

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.

Cross-modal fusion of cytomorphology and 18F-FDG PET/CT for non-invasive bone marrow immune microenvironment decoding in multiple myeloma

Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma

For patients with relapsed or refractory multiple myeloma (RRMM), the addition of the oral drug mezigdomide to standard treatment with carfilzomib and dexamethasone markedly improved progression-free survival over standard treatment alone, according to results from a phase 3 clinical trial led by investigators at Dana-Farber Cancer Institute.

  • by

  • May 29, 2026

  • 5 min